Molecular targets for antiviral agents

Journal of Pharmacology and Experimental Therapeutics

Volumn 297, Issue 1, 2001, Pages 1-10

  De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 3 DEAZANEPLANOCIN A; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 5 ETHYNYL 4 IMIDAZOLECARBOXAMIDE 1 RIBOSIDE; ACICLOVIR; ACYCLIC NUCLEOSIDE; ADEFOVIR DIPIVOXIL; ADENOSINE DERIVATIVE; ANTIVIRUS AGENT; CIDOFOVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; LAMIVUDINE; MYCOPHENOLIC ACID; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NEPLANOCIN A; NEVIRAPINE; RECEPTOR ANTIBODY; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; VALACICLOVIR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOMEGALOVIRUS; DRUG MECHANISM; EBOLA VIRUS; HEPATITIS B VIRUS; HERPES SIMPLEX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS; METHYLATION; ORTHOMYXOVIRUS; PARAMYXOVIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVERSE TRANSCRIPTION; RNA SYNTHESIS; VARICELLA ZOSTER VIRUS; VIRUS ADSORPTION; VIRUS INFECTION; VIRUS REPLICATION; WART VIRUS;

EID: 0035087778     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro
2. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative
3. Cyclosaligenyl-2′,3′-didehydro-2′,3′-dideoxythymidine monophosphate: Efficient intracellular delivery of d4TMP
4. Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1
5. Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]
6. Extension of the polyanionic cosalane pharmacophore as a strategy for increasing anti-HIV potency
7. A second target for the peptoid tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry
8. S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents
9. Therapeutic potential of HPMPC as an antiviral drug
10. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections
11. Virus replication: Target functions and events for virus-specific inhibitors
12. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
13. Novel compounds in preclinical/early clinical development for the treatment of HIV infections
14. CXCR4 and CCR5 chemokine receptor antagonists as anti-HIV agents, with special emphasis on the CXCR4 antagonist AMD-3100
15. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists
16. Antiviral drugs: Current state of the art
17. Antiviral therapy of herpesvirus infections
18. Antiviral activity of nucleoside analogues: The BVDU connection
19. Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5′-nor derivatives
20. Antiviral activities of 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide and related compounds
21. (E)-5-(2-Bromovinyl)-2′-deoxyuridine: A potent and selective anti-herpes agent
22. (S)-9-(2,3-dihydroxypropyl)adenine: An aliphatic nucleoside analog with broad-spectrum antiviral activity
23. A novel selective broad-spectrum anti-DNA virus agent
24. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (zintevir)
25. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein
26. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers
27. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model
28. The HIV-1 reverse transcription (RT) process as target for RT inhibitors
29. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain
30. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections
31. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo
32. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
33. Mutational analysis of Trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors
34. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters
35. Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine
36. Cidofovir in the treatment of HPV-associated lesions
37. The cyclohexene ring system as a furanose mimic: Synthesis and antiviral activity of both enantiomers of cyclohexenylguanine
38. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle
39. Potent anti-HIV (type 1 and type 2) activity of polyoxometalates: Structure-activity relationship and mechanism of action